Poltreg S.A. (PTG.WA)
PLN 35.0
(4.17%)
PLN 35.0
(4.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.38 Million PLN | -1018.55% |
| 2022 | -124 Thousand PLN | -115.18% |
| 2021 | 817 Thousand PLN | 78.77% |
| 2020 | 457 Thousand PLN | 105.86% |
| 2019 | 222 Thousand PLN | 311.43% |
| 2018 | -105 Thousand PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -683 Thousand PLN | -83.11% |
| 2024 Q2 | -1.33 Million PLN | -95.75% |
| 2023 Q2 | -155 Thousand PLN | -518.92% |
| 2023 Q4 | -373 Thousand PLN | 58.37% |
| 2023 FY | -1.38 Million PLN | -1018.55% |
| 2023 Q1 | 37 Thousand PLN | 116.37% |
| 2023 Q3 | -896 Thousand PLN | -478.06% |
| 2022 FY | -124 Thousand PLN | -115.18% |
| 2022 Q4 | -226 Thousand PLN | -209.59% |
| 2022 Q3 | -73 Thousand PLN | -142.69% |
| 2022 Q2 | 171 Thousand PLN | 4175.0% |
| 2022 Q1 | 4000.00 PLN | -99.06% |
| 2021 Q1 | -42 Thousand PLN | -123.6% |
| 2021 FY | 817 Thousand PLN | 78.77% |
| 2021 Q4 | 426 Thousand PLN | 206.47% |
| 2021 Q3 | 139 Thousand PLN | -52.72% |
| 2021 Q2 | 294 Thousand PLN | 800.0% |
| 2020 Q2 | 40 Thousand PLN | 0.0% |
| 2020 Q3 | 199 Thousand PLN | 397.5% |
| 2020 Q4 | 178 Thousand PLN | -10.55% |
| 2020 FY | 457 Thousand PLN | 105.86% |
| 2020 Q1 | 40 Thousand PLN | 0.0% |
| 2019 FY | 222 Thousand PLN | 311.43% |
| 2018 FY | -105 Thousand PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioceltix S.A. | -1.03 Million PLN | -33.613% |
| BIOTON S.A. | 72.85 Million PLN | 101.904% |
| Captor Therapeutics Spolka Akcyjna | 6.9 Million PLN | 120.099% |
| Mabion S.A. | 114.58 Million PLN | 101.21% |
| Molecure S.A. | -4.1 Million PLN | 66.184% |
| NanoGroup S.A. | -79.01 Thousand PLN | -1655.318% |
| Pharmena S.A. | 5.84 Million PLN | 123.738% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 46.115% |
| Ryvu Therapeutics S.A. | 29.3 Million PLN | 104.733% |
| Synthaverse S.A. | 35.16 Million PLN | 103.944% |
| Urteste S.A. | -479 Thousand PLN | -189.562% |